An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer

被引:1
作者
Rosati, Gerardo [1 ]
Montrone, Michele [2 ]
Pacilio, Carmen [3 ]
Colombo, Alfredo [4 ]
Cicero, Giuseppe [5 ]
Paragliola, Fernando [1 ]
Vaia, Angelo [1 ]
Annunziata, Luigi [1 ]
Bilancia, Domenico [1 ]
机构
[1] San Carlo Hosp, Med Oncol Unit, I-85100 Potenza, Italy
[2] IRCCS Ist Tumori Giovanni Paolo 2, Med Thorac Oncol Unit, I-70124 Bari, Italy
[3] IRCCS Ist Tumori G Pascale, Med Breast Canc Dept, I-80131 Naples, Italy
[4] CDC Macchiarella, Med Oncol Unit, I-90138 Palermo, Italy
[5] Univdegli Studi Palermo, Med Oncol, I-90133 Palermo, Italy
关键词
cetuximab; metastatic colorectal cancer; older patients; panitumumab; CETUXIMAB PLUS CAPECITABINE; SINGLE-AGENT PANITUMUMAB; FRAIL ELDERLY-PATIENTS; RANDOMIZED PHASE-III; 1ST-LINE TREATMENT; INTERNATIONAL-SOCIETY; OPEN-LABEL; GERIATRIC ASSESSMENT; POOLED ANALYSIS; IRINOTECAN;
D O I
10.3390/jcm11237108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when chemotherapy is combined with monoclonal antibodies (bevacizumab, cetuximab, and panitumumab). Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients.
引用
收藏
页数:15
相关论文
共 45 条
  • [1] Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC)
    Abdelwahab, S.
    Azmy, A.
    Abdel-aziz, H.
    Salim, H.
    Mahmoud, A.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (09) : 1487 - 1492
  • [2] [Anonymous], NUMERI CANCRO ITALIA
  • [3] Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
    Bokemeyer, Carsten
    Van Cutsem, Eric
    Rougier, Philippe
    Ciardiello, Fortunato
    Heeger, Steffen
    Schlichting, Michael
    Celik, Ilhan
    Koehne, Claus-Henning
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) : 1466 - 1475
  • [4] Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer
    Bouchahda, M.
    Macarulla, T.
    Spano, J. P.
    Bachet, J. B.
    Lledo, G.
    Andre, T.
    Landi, B.
    Tabernero, J.
    Karaboue, A.
    Domont, J.
    Levi, F.
    Rougier, P.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 67 (03) : 255 - 262
  • [5] Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
    Cassidy, James
    Saltz, Leonard B.
    Giantonio, Bruce J.
    Kabbinavar, Fairooz F.
    Hurwitz, Herbert I.
    Rohr, Ulrich-Peter
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (05) : 737 - 743
  • [6] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    Cunningham, David
    Lang, Istvan
    Marcuello, Eugenio
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dong Bok
    Jonker, Derek
    Osborne, Stuart
    Andre, Niko
    Waterkamp, Daniel
    Saunders, Mark P.
    [J]. LANCET ONCOLOGY, 2013, 14 (11) : 1077 - 1085
  • [7] Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
    Douillard, J. Y.
    Siena, S.
    Cassidy, J.
    Tabernero, J.
    Burkes, R.
    Barugel, M.
    Humblet, Y.
    Bodoky, G.
    Cunningham, D.
    Jassem, J.
    Rivera, F.
    Kocakova, I.
    Ruff, P.
    Blasinska-Morawiec, M.
    Smakal, M.
    Canon, J. L.
    Rother, M.
    Oliner, K. S.
    Tian, Y.
    Xu, F.
    Sidhu, R.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (07) : 1346 - 1355
  • [8] Douillard J.Y., 2014, ANN ONCOL, V25, P187, DOI [10.1093/annonc/mdu333.49, DOI 10.1093/ANNONC/MDU333.49]
  • [9] Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)
    Extermann, M
    Aapro, M
    Bernabei, RB
    Cohen, HJ
    Droz, JP
    Lichtman, S
    Mor, V
    Monfardini, S
    Repetto, L
    Sorbye, L
    Topinkova, E
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (03) : 241 - 252
  • [10] A global view on cancer incidence and national levels of the human development index
    Fidler, Miranda M.
    Soerjomataram, Isabelle
    Bray, Freddie
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (11) : 2436 - 2446